Lesinurad
- TRADE NAMES: Duzallo (AstraZeneca); Zurampic (AstraZeneca)
- INDICATIONS: Gout-associated hyperuricemia (in combination with a xanthine oxidase inhibitor)
- CLASS: URAT1 inhibitor, Uricosuric
- HALF-LIFE: 5 hours
FDA APPROVAL DATE: 12/22/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Amiodarone, Carbamazepine, CYP2C9 inducers or inhibitors, CYP3A substrates, Fluconazole, Rifampin, Valproic Acid
PREGNANCY CATEGORY: N/A
No available data
Contra-indicated in patients with severe renal impairment (including end stage renal disease, kidney transplant recipients or patients on dialysis), tumor lysis syndrome or Lesch-Nylan syndrome.
Duzallo is lesinurad and allopurinol (see separate entry).
RISK OF ACUTE RENAL FAILURE, MORE COMMON WHEN USED WITHOUT A XANTHINE OXIDASE INHIBITOR
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
Page last updated 08/31/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
